All Outputs (3)

PGC1β activates an antiangiogenic program to repress neoangiogenesis in muscle ischemia (2014)
Journal Article
Yadav, V., Matsakas, A., Lorca, S., & Narkar, V. A. (2014). PGC1β activates an antiangiogenic program to repress neoangiogenesis in muscle ischemia. Cell reports, 8(3), 783-797. https://doi.org/10.1016/j.celrep.2014.06.040

Revascularization of ischemic skeletalmuscle is governed by a balance between pro- and antiangiogenic factors in multiple cell types but particularly in myocytes and endothelial cells. Whereas the regulators of proangiogenic factors are well defined... Read More about PGC1β activates an antiangiogenic program to repress neoangiogenesis in muscle ischemia.

Myostatin tilts the balance between skeletal muscle size, function and metabolism (2014)
Journal Article
Matsakas, A. (2014). Myostatin tilts the balance between skeletal muscle size, function and metabolism. Experimental Physiology, 99(3), 469-470. https://doi.org/10.1113/expphysiol.2013.076422

Propeptide-mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice (2014)
Journal Article
Collins-Hooper, H., Sartori, R., Macharia, R., Visanuvimol, K., Foster, K., Matsakas, A., …Patel, K. (2014). Propeptide-mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice. The journals of gerontology. Series A, Biological sciences and medical sciences, 69(9), 1049-1059. https://doi.org/10.1093/gerona/glt170

Mammalian aging is accompanied by a progressive loss of skeletal muscle, a process called sarcopenia. Myostatin, a secreted member of the transforming growth factor-β family of signaling molecules, has been shown to be a potent inhibitor of muscle gr... Read More about Propeptide-mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice.